Domestic pharma companies have the potential to grow their revenue from the US by almost five times at around $30 billion from $6.5 billion in 2018 if they properly tap just 10 of the widely consumed drugs in the world’s largest drug market, according to an analysis by the World Trade Centre.
Despite being the largest export market for domestic pharma makers, they served only a miniscule 5.6 per cent or $6.5 billion of the over $116 billion American pharma imports of in 2018, show the WTC data.
Despite having good demand from across the markets, primarily due to lower prices and easy availability, India controls only 2.4 per cent of global pharma exports.
With robust manufacturing capabilities, domestic pharma companies have the potential to enhance their exports to the US by almost five times to $29.6 billion, says the WTC in a note quoting data from the UN’s International Trade Commission.
The WTC has identified 10 products that constitute about 25 per cent of American pharma imports in 2018 at USD 29.6 billion which constitute about 17 per cent of US imports from India.
These ten products include single vitamins, medicaments affecting central nervous system, cough & cold preparations, dermatological agents & local anesthetics, chemical contraceptives, sterile surgical catgut, antineoplastic & immunosupressive medicaments, and structural analogues among others.
These 10 products constitute around 25 per cent of American drug imports and but the share of Indian companies in 2018 was only worth $1 billion.
Domestic pharma companies shipped products worth $6.53 billion in 2018 to the US, which was only 5.61 per cent of total American imports worth $116.35 billion, showed WTC data.-Business Standard